Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Weishaar

Retina Specialist Wichita, KS Medical Doctor

NPI 1548261696 CMS profile 296260

530 N Lorraine St, Wichita, KS 67214

Open in the dashboard

General payments

$16,670

221 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$115,669

6 holdings reported · through program year 2025

Research they led as principal investigator

$609,229 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Paul Weishaar of Wichita, KS is reported in the CMS Open Payments database as having received $16,670 across 221 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $609,229 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $115,669 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 82nd percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,545 44
2024 General $1,692 43
2023 General $1,075 30
2022 General $3,681 38
2021 General $2,964 24
2020 General $1,243 11
2019 General $4,469 31
2024 Ownership $28,668 1
2023 Ownership $28,668 1
2022 Ownership $12,500 1
2021 Ownership $12,500 1
2020 Ownership $16,667 1
2019 Ownership $16,667 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Weishaar
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Paul Weishaar were reported at $1,545. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Paul Weishaar Retina Specialist median Middle half National median
2019 $4,469 $410 $157–$1,517 $163
2020 $1,243 $168 $65–$778 $114
2021 $2,964 $258 $101–$1,161 $132
2022 $3,681 $418 $162–$1,488 $149
2023 $1,075 $476 $178–$1,312 $160
2024 $1,692 $520 $188–$1,372 $164
2025 $1,545 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. US Retina LLC $6,800 5 payments
  2. Genentech USA, Inc. $2,052 49 payments
  3. Dutch Ophthalmic, USA $1,500 1 payment
  4. Genentech, Inc. $1,007 7 payments
  5. Apellis Pharmaceuticals, Inc. $805 12 payments
  6. AbbVie, Inc. $508 21 payments
  7. Allergan Inc. $420 13 payments
  8. ANI Pharmaceuticals, Inc. $406 12 payments
  9. Alimera Sciences, Inc. $400 15 payments
  10. Regeneron Healthcare Solutions, Inc. $350 14 payments
  11. Other $2,421 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,756 211 payments
  2. Current or prospective ownership or investment interest $6,800 5 payments
  3. Consulting Fee $1,500 1 payment
  4. Travel and Lodging $594 3 payments
  5. Gift $19 1 payment
Products named General payments · program years 2019–2025
  1. VABYSMO $1,609 35 payments
  2. EVA Ophthalmic Surgical System $1,500 1 payment
  3. Non-Covered Product $966 5 payments
  4. Syfovre $656 10 payments
  5. OZURDEX Retina $496 17 payments
  6. SUSVIMO $417 11 payments
  7. OZURDEX Eye Care $377 14 payments
  8. Lucentis $366 9 payments
  9. ILUVIEN $333 11 payments
  10. YUTIQ $309 10 payments
  11. Other $3,182 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,128

Median for Ophthalmology: 891

Drug cost

$18,102

Median for Ophthalmology: $68,233

Branded share of claims

19.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 260 $7,354
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 199 $3,009
Latanoprost Generic 430 $2,327
Simbrinza Brinzolamide/Brimonidine Tart Brand 11 $2,132
Brimonidine Tartrate Generic 46 $1,003
Ketorolac Tromethamine Generic 31 $832
Dorzolamide Hcl Generic 39 $535
Timolol Maleate Generic 76 $516
Atropine Sulfate Generic 11 $256
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $78

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$3,349,937

Of which drugs: $2,831,495

Medicare patients

1,138

Average age 77

Services billed

65,143

666 women, 472 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 40%
Ischemic heart disease 30%
Chronic kidney disease 30%
Depression 22%
Atrial fibrillation 19%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, faricimab-svoa, 0.1 mg J2777 Office 203 53,100 $1,447,856
Injection, aflibercept, 1 mg J0178 Office 153 1,144 $755,062
Injection, aflibercept hd, 1 mg J0177 Office 40 984 $259,225
Injection, avacincaptad pegol, 0.1 mg J2782 Office 15 1,160 $100,250
Injection, dexamethasone, intravitreal implant, 0.1 mg J7312 Office 36 385 $62,045
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg Q5128 Office 26 287 $48,283
Injection, ranibizumab, 0.1 mg J2778 Office 31 238 $33,319
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 18 84 $61

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VABYSMO
  • Genentech USA, Inc. $355
$355 — 53,100
Syfovre
  • Apellis Pharmaceuticals, Inc. $252
$252 — —
Izervay
  • Astellas Pharma US Inc $184
$184 — 1,160
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $173
$173 — —
ILUVIEN
  • Alimera Sciences, Inc. $120
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record